Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice.

ABSTRACT:

Background

Currently, metastatic hormone-sensitive prostate cancer (mHSPC) patients are often treated with docetaxel chemotherapy at the initiation of hormonal therapy. This treatment is based on the results of two pivotal trials. However, trial populations are not a representative of real-world patient populations.

Objective

We aimed to analyze whether survival rates in our daily practice cohort is comparable with those in clinical trials and to characterize the tolerability of docetaxel chemotherapy in daily practice.

Design setting and participants

In this retrospective cohort analysis, we studied 159 mHSPC patients treated with early docetaxel from April 2014 up to June 2020 in a top clinical hospital in The Netherlands. Patients were selected using hospital pharm

SUBMITTER: de Groot I 

PROVIDER: S-EPMC8546919 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature